---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-102489"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:39:41.776143+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences reports positive interim SGT-003 data; microdystrophin expression 60% at Day 90, 91% at Day 360

## Summary
- 40 participants dosed; SGT-003 well tolerated with steroid-only immunomodulation regimen.
- Day 90 biopsy (n=20): mean microdystrophin expression 60% (western blot), 63% positive fibers; 60% beta-sarcoglycan restoration.
- Day 360 biopsy (n=3): microdystrophin expression 91% (western blot), 69% positive fibers; 69% beta-sarcoglycan restoration.
- Biomarker improvements: CK -38%, ALT -43%, AST -30%, LDH -46%, eMHC -44% at Day 90.
- FDA aligned on Phase 3 design; screening underway; first participant dosing expected Q1 2026; accelerated approval discussions planned.

## SEC filing metadata
- accession: 0001193125-26-102489
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312526102489/0001193125-26-102489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312526102489/sldb-20260311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-102489
- JSON: https://secwatch.observer/filing/0001193125-26-102489.json
- Plain text: https://secwatch.observer/filing/0001193125-26-102489.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.